keyword
MENU ▼
Read by QxMD icon Read
search

5-ARI

keyword
https://www.readbyqxmd.com/read/28791232/optimising-patient-outcomes-with-photoselective-vaporization-of-the-prostate-pvp-a-review
#1
REVIEW
Claire Pascoe, Darren Ow, Marlon Perera, Henry H Woo, Greg Jack, Nathan Lawrentschuk
Benign prostatic hyperplasia (BPH) is a common pathology causing lower urinary tract symptoms (LUTS) and may significantly impact quality of life. While transurethral resection of the prostate (TURP) remains the gold standard treatment, there are many evolving technologies that are gaining popularity. Photoselective vaporization of the prostate (PVP) is one such therapy which has been shown to be non-inferior to TURP. We aimed to review the literature and discuss factors to optimise patient outcomes in the setting of PVP for BPH...
July 2017: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28789947/impact-of-5%C3%AE-reductase-inhibitors-on-disease-reclassification-among-men-on-active-surveillance-for-localized-prostate-cancer-with-favorable-features
#2
Charles Dai, Vishnu Ganesan, Joseph Zabell, Yaw A Nyame, Nima Almassi, Daniel J Greene, Daniel Hettel, Chad Reichard, Samuel C Haywood, Hans Arora, Anna Zampini, Alice Crane, Jianbo Li, Ahmed Elshafei, Cristina Magi-Galluzzi, Robert J Stein, Khaled Fareed, Michael Gong, J Stephen Jones, Eric A Klein, Andrew J Stephenson
PURPOSE: To determine the effect of 5α-reductase inhibitors (5-ARI) on disease reclassification in men with prostate cancer optimally selected for active surveillance (AS). MATERIALS AND METHODS: A retrospective review identified 635 patients on AS between 2002-2015. Patients with favorable cancer features on repeat biopsy, defined as absence of Gleason upgrading, were included in the cohort. Patients were stratified by those who did or did not receive finasteride/dutasteride within 1 year of diagnosis...
August 5, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28695317/pre-radiotherapy-psa-progression-is-a%C3%A2-negative-prognostic-factor-in-prostate-cancer-patients-using-5%C3%A2-alpha-reductase-inhibitors
#3
Daniel Taussky, Julie Piotte, Kevin C Zorn, Marc Zanaty, Vimal Krishnan, Carole Lambert, Jean-Paul Bahary, Marie-Claude Beauchemin, Maroie Barkati, Cynthia Ménard, Guila Delouya
OBJECTIVE: To investigate the impact of 5‑alpha-reductase inhibitor (5-ARI) use on radiotherapy outcomes for localized prostate cancer. PATIENTS AND METHODS: We included 203 patients on a 5-ARI from our institutional database comprising over 2500 patients who had been treated with either external beam radiotherapy (EBRT) or brachytherapy for localized prostate cancer. Patients received a 5-ARI for urinary symptoms or active surveillance. Cancer progressions at the time of definitive treatment were analyzed according to the following criteria: (a) progression of Gleason score or increase in cancer volume on biopsy, (b) first biopsy positive for cancer after being treated for urinary symptoms with a 5-ARI, and (c) prostate-specific antigen (PSA) progression with or without a previous cancer diagnosis...
July 10, 2017: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/28580382/differences-in-the-treatment-of-benign-prostatic-hyperplasia-comparing-the-primary-care-physician-and-the-urologist
#4
Adam J Rensing, Adrienne Kuxhausen, Joel Vetter, Seth A Strope
INTRODUCTION: Benign prostatic hyperplasia is a prevalent chronic condition with expenditures exceeding $1 billion each year. Little is known about management of patients by primary care physicians compared to urologists. We assessed changes in management after medication initiation in these two settings. METHODS: From the Chronic Condition Warehouse 5% sample of Medicare beneficiaries linked to Medicare Part D data, we defined a cohort of men, 66 to 90 years old, with initial prescriptions for alpha-blocker, 5-alpha reductase inhibitor (5-ARI), or both...
May 2017: Urology Practice
https://www.readbyqxmd.com/read/28385453/co-clinical-analysis-of-a-genetically-engineered-mouse-model-and-human-prostate-cancer-reveals-significance-of-nkx3-1-expression-for-response-to-5%C3%AE-reductase-inhibition
#5
Aditya Dutta, Sukanya Panja, Renu K Virk, Jaime Yeji Kim, Roseann Zott, Serge Cremers, David M Golombos, Deli Liu, Juan Miguel Mosquera, Elahe A Mostaghel, Christopher E Barbieri, Antonina Mitrofanova, Cory Abate-Shen
BACKGROUND: Although men on active surveillance for prostate cancer (PCa) may benefit from intervention with 5α-reductase inhibitors (5-ARIs), it has not been resolved whether 5-ARIs are effective for delaying disease progression and, if so, whether specific patients are more likely to benefit. OBJECTIVE: To identify molecular features predictive of patient response to 5-ARIs. DESIGN, SETTING, AND PARTICIPANTS: Nkx3.1 mutant mice, a model of early-stage PCa, were treated with the 5-ARI finasteride, and histopathological and molecular analyses were performed...
April 3, 2017: European Urology
https://www.readbyqxmd.com/read/28216328/outcomes-of-prostate-cancer-screening-by-5%C3%AE-reductase-inhibitor-use
#6
Teemu J Murtola, Anniina Virkku, Kirsi Talala, Ulf-Håkan Stenman, Kimmo Taari, Teuvo L J Tammela, Anssi Auvinen
PURPOSE: Prostate cancer screening with prostate specific antigen reduces prostate cancer mortality but leads to over diagnosis of indolent prostate cancer. The use of 5α-reductase inhibitors lowers prostate specific antigen and in theory could affect the performance of prostate specific antigen based screening. We evaluated the outcomes of prostate cancer screening in 5α-reductase inhibitors users. MATERIALS AND METHODS: The study was performed in FinRSPC (Finnish Randomized Study of Screening for Prostate Cancer)...
February 16, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28164396/improved-multiparametric-mri-discrimination-between-low-risk-prostate-cancer-and-benign-tissues-in-a-small-cohort-of-5%C3%AE-reductase-inhibitor-treated-individuals-as-compared-with-an-untreated-cohort
#7
Olga Starobinets, John Kurhanewicz, Susan M Noworolski
The purpose of this study was to determine whether 5α-reductase inhibitors (5-ARIs) affect the discrimination between low-grade prostate cancer and benign tissues on multiparametric MRI (mpMRI). Twenty men with biopsy-proven Gleason 3 + 3 prostate cancer and 3 T mpMRI were studied. Ten patients (Tx) had been receiving 5-ARIs for at least a year at scan time. Ten untreated patients (Un) were matched to the treated cohort. For each subject two regions of interest representing cancerous and benign tissues were drawn within the peripheral zone of each prostate, MR measures evaluated, and cancer contrast versus benign (contrast = (MRTumor  - MRHealthy )/MRHealthy ) calculated...
May 2017: NMR in Biomedicine
https://www.readbyqxmd.com/read/28126151/5-alpha-reductase-inhibitors-and-the-risk-of-prostate-cancer-mortality-in-men-treated-for-benign-prostatic-hyperplasia
#8
COMPARATIVE STUDY
Lauren P Wallner, Julia R DiBello, Bonnie H Li, Stephen K Van Den Eeden, Sheila Weinmann, Debra P Ritzwoller, Jill E Abell, Ralph D'Agostino, Ronald K Loo, David S Aaronson, Kathryn Richert-Boe, Ralph I Horwitz, Steven J Jacobsen
OBJECTIVE: To compare the risk of prostate cancer mortality among men treated with 5- alpha reductase inhibitors (5-ARIs) with those treated with alpha-adrenergic blockers (ABs) in community practice settings. PATIENTS AND METHODS: A retrospective matched cohort (N=174,895) and nested case-control study (N=18,311) were conducted in 4 regions of an integrated health care system. Men 50 years and older who initiated pharmaceutical treatment for benign prostatic hyperplasia between January 1, 1992, and December 31, 2007, and had at least 3 consecutive prescriptions were followed through December 31, 2010...
December 2016: Mayo Clinic Proceedings
https://www.readbyqxmd.com/read/28075168/transurethral-resection-of-prostate-and-bleeding-a-prospective-randomized-double-blind-placebo-controlled-trial-to-see-efficacy-of-short-term-use-of-finasteride-and-dutasteride-on-operative-blood-loss-and-prostatic-micro-vessel-density
#9
Ankur Bansal, Aditi Arora
OBJECTIVE: To determine the efficacy of short duration use of finasteride and dutasteride prior to transurethral resection of prostate (TURP) on intraoperative blood loss and microvessel density (MVD) of prostate stroma and suburethral tissues in benign prostatic hyperplasia (BPH) Methods: This study includes 450 patients who were planned for TURP. They were prospectively randomized into three groups (150 patients each). Group 1 received placebo, group 2 received finasteride 5 mg/day and group 3 patients received dutasteride 0...
January 11, 2017: Journal of Endourology
https://www.readbyqxmd.com/read/27928428/evidence-for-the-efficacy-and-safety-of-tadalafil-and-finasteride-in-combination-for-the-treatment-of-lower-urinary-tract-symptoms-and-erectile-dysfunction-in-men-with-benign-prostatic-hyperplasia
#10
REVIEW
Chris Olesovsky, Anil Kapoor
Benign prostatic hyperplasia (BPH) is an age-related phenomenon associated with prostatic enlargement and bladder outlet obstruction that can cause significant lower urinary tract symptoms (LUTS). These LUTS have a negative impact on an individual's quality of life, which is why treatment of symptomatic BPH has become a major priority. Although surgical interventions exist for treating BPH, pharmacological therapies are often preferred due to their minimal invasiveness and high degree of effectiveness. The three classes of drugs approved for treating BPH include α-blockers, 5-α-reductase inhibitors (5-ARIs) and phosphodiesterase 5 (PDE-5) inhibitors...
August 2016: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/27580700/rates-of-prostate-surgery-and-acute-urinary-retention-for-benign-prostatic-hyperplasia-in-men-treated-with-dutasteride-or-finasteride
#11
COMPARATIVE STUDY
Josephina G Kuiper, Irene D Bezemer, Maurice T Driessen, Averyan Vasylyev, Claus G Roehrborn, Fernie J A Penning-van Beest, Ron M C Herings
BACKGROUND: Previous studies have suggested a greater benefit for various outcomes in men diagnosed with benign prostatic hyperplasia (BPH) who are treated with dutasteride than for men treated with finasteride. This study investigates whether the rates of BPH-related prostate surgery and acute urinary retention (AUR) differ between dutasteride and finasteride users in the Netherlands. METHODS: From the PHARMO Database Network, men aged ≥50 years with a dispensing of dutasteride or finasteride with or without concomitant alpha-blocker treatment between March 1, 2003 and December 31, 2011 were selected...
August 31, 2016: BMC Urology
https://www.readbyqxmd.com/read/27310433/impact-of-combination-therapy-5-alpha-reductase-inhibitors-5-ari-plus-alpha-blockers-ab-on-erectile-dysfunction-and-decrease-of-libido-in-patients-with-luts-bph-a-systematic-review-with-meta-analysis
#12
REVIEW
Vincenzo Favilla, Giorgio Ivan Russo, Salvatore Privitera, Tommaso Castelli, Raimondo Giardina, Aldo E Calogero, Rosita A Condorelli, Sandro La Vignera, Sebastiano Cimino, Giuseppe Morgia
Lower urinary tract symptoms (LUTS) secondary to benign prostatic obstruction (BPO) represent one of the most common clinical complaints in adult men. Several drugs used for LUTS/BPO may strongly affect sexual function and bother. The aim of this systematic review and meta-analysis was to evaluate the impact of combination therapy with alpha-blockers (AB), 5-alpha reductase inhibitors (5-ARI) on the risk of erectile dysfunction(ED) and libido alterations (LA) from randomized clinical trial (RCT). Based on the inclusion and exclusion criteria, five RCTs involving 6131 patients were included in the analysis...
September 2016: Aging Male: the Official Journal of the International Society for the Study of the Aging Male
https://www.readbyqxmd.com/read/26957512/prostate-cancer-prevention-concepts-and-clinical-trials
#13
REVIEW
Zachary Hamilton, J Kellogg Parsons
Prevention is an important treatment strategy for diminishing prostate cancer morbidity and mortality and is applicable to both early- and late-stage disease. There are three basic classifications of cancer prevention: primary (prevention of incident disease), secondary (identification and treatment of preclinical disease), and tertiary (prevention of progression or recurrence). Based on level I evidence, 5-alpha reductase inhibitors (5-ARIs) should be considered in selected men to prevent incident prostate cancer...
April 2016: Current Urology Reports
https://www.readbyqxmd.com/read/26872842/patterns-of-care-for-newly-diagnosed-benign-prostatic-hyperplasia-in-the-united-states
#14
J Quentin Clemens, Howard B Goldman, Kelly H Zou, Xuemei Luo, David Russell, Douglass S Chapman, Canan B Esinduy, Jennifer T Anger
PURPOSE: We examined diagnostic tests and treatment patterns in men with new onset benign prostatic hyperplasia using consolidated national electronic health record data. MATERIALS AND METHODS: The Humedica® electronic health record database consists of de-identified patient records from approximately 25 million patients in the United States. Using this database, men with a new benign prostatic hyperplasia diagnosis (benign prostatic hyperplasia, bladder neck obstruction, urinary retention and incomplete bladder emptying) between July 1, 2009 and June 30, 2012 were included in study...
July 2016: Journal of Urology
https://www.readbyqxmd.com/read/26804670/5-alpha-reductase-inhibitor-use-and-prostate-cancer-survival-in-the-finnish-prostate-cancer-screening-trial
#15
Teemu J Murtola, Elina K Karppa, Kimmo Taari, Kirsi Talala, Teuvo L J Tammela, Anssi Auvinen
Randomized clinical trials have shown that use of 5α-reductase inhibitors (5-ARIs) lowers overall prostate cancer (PCa) risk compared to placebo, while the proportion of Gleason 8-10 tumors is elevated. It is unknown whether this affects PCa-specific survival. We studied disease-specific survival by 5-ARI usage in a cohort of 6,537 prostate cancer cases diagnosed in the Finnish Prostate Cancer Screening Trial and linked to the national prescription database for information on medication use. Cox proportional hazards regression was used to estimate hazard ratios and 95% confidence intervals for prostate cancer-specific deaths...
June 15, 2016: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/26766804/comments-concerning-the-real-risk-of-sexual-adverse-events-secondary-to-the-use-of-5-aris
#16
Furio Pirozzi Farina, Antonella Pischedda
Treatment-induced sexual dysfunctions (SD) are a recurrent and controversial topic in recent literature on the adverse events related to the use of 5-alpha-reductase inhibitors (5ARIs) (1, 2). In order to deal adequately with the various aspects of this topic, it is necessary to first cover some of the steps that allow a better definition and understanding of the subject.
December 2015: Archivio Italiano di Urologia, Andrologia
https://www.readbyqxmd.com/read/26569417/sexual-dysfunction-related-to-drugs-a-critical-review-part-v-%C3%AE-blocker-and-5-ari-drugs
#17
REVIEW
A La Torre, G Giupponi, D Duffy, A Conca, T Cai, A Scardigli
UNLABELLED: Sexual dysfunction is a potential side effect of BPH (benign prostatic hyperplasia) and LUTS (lower urinary tract symptoms) drugs: this article is a critical review of the current literature. Many studies have been published on this topic. Methodological flaws limit the conclusions of these studies, mainly because of the lack of diagnostic criteria for ejaculatory and sexual desire dysfunction. Few of these studies are RCTs. The α-blocker (also called α1-adrenergic antagonist, alpha-adrenoceptor antagonist, alpha-blocker or AB) and 5-ARI (also called 5α-reductase inhibitor or testosterone-5-alpha reductase inhibitor) drugs can in particular cause erectile dysfunction, ejaculatory disorders and reduction of sexual desire...
January 2016: Pharmacopsychiatry
https://www.readbyqxmd.com/read/26469978/risk-of-fractures-and-falls-during-and-after-5-%C3%AE-reductase-inhibitor-use-a-nationwide-cohort-study
#18
COMPARATIVE STUDY
David Robinson, Hans Garmo, Pär Stattin, Karl Michaëlsson
BACKGROUND: Lower urinary tract symptoms are common among older men and 5-α reductase inhibitors (5-ARI) are a group of drugs recommended in treating these symptoms. The effect on prostate volume is mediated by a reduction in dihydrotestosterone; however, this reduction is counterbalanced by a 25% rise in serum testosterone levels. Therefore, 5-ARI use might have systemic effects and differentially affect bone mineral density, muscular mass and strength, as well as falls, all of which are major determinants of fractures in older men...
2015: PloS One
https://www.readbyqxmd.com/read/26388319/impairment-of-dynamic-pressure-autoregulation-precedes-clinical-deterioration-after-aneurysmal-subarachnoid-hemorrhage
#19
Johann Fontana, Holger Wenz, Kirsten Schmieder, Martin Barth
BACKGROUND: This study was designed to evaluate the potential of the dynamic autoregulation index (ARI) to serve as an early warning system for an imminent clinical deterioration after subarachnoid hemorrhage (SAH). METHODS: All patients received a baseline digital subtraction angiography and a computed tomography (CT) prior to treatment. The clinical status, the ARI, and the transcranial Doppler (TCD) values were evaluated daily until discharge from the intensive care unit (ICU)...
May 2016: Journal of Neuroimaging: Official Journal of the American Society of Neuroimaging
https://www.readbyqxmd.com/read/26380371/shear-bond-strength-of-orthodontic-brackets-fixed-with-remineralizing-adhesive-systems-after-simulating-one-year-of-orthodontic-treatment
#20
Gisele Lima Bezerra, Carlos Rocha Gomes Torres, Mateus Rodrigues Tonetto, Alvaro Henrique Borges, Milton Carlos Kuga, Matheus Coelho Bandeca, Leily Macedo Firoozmand
The objective of this study is to assess, in vitro, the shear bond strength of orthodontic brackets fixed with remineralizing adhesive systems submitted to thermomechanical cycling, simulating one year of orthodontic treatment. Sixty-four bovine incisor teeth were randomly divided into 4 experimental groups (n = 16): XT: Transbond XT, QC: Quick Cure, OL: Ortholite Color, and SEP: Transbond Plus Self-Etching Primer. The samples were submitted to thermomechanical cycling simulating one year of orthodontic treatment...
2015: TheScientificWorldJournal
keyword
keyword
68180
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"